Drug Control Act; adds certain chemicals to the Act.
Do you support it?
Want to know if it passes?
We'll email you when SB 759 moves — a committee vote, a floor vote, or a signature. Nothing else.
Free forever · unsubscribe in one click.
Your answer was recorded either way.
Which district are you in?
Your ZIP is all we need to match you to your own representatives — so we can tell you how they voted on SB 759.
You're tracking SB 759
We'll email you the moment it moves.
SB 759 — Drug Control Act; adds certain chemicals to the Act.
Last action — Approved by Governor-Chapter 115 (effective 7/1/22)
No card. One bill, free forever — alerts when it moves.
-
✓Introduced
-
✓In Committee
-
✓Passed Senate
-
✓Passed House of Delegates
-
✓To Executive
-
6Enacted
This bill has been enacted into law. Introduced January 21, 2022. Enacted.
Signed by Governor Glenn Youngkin (Republican) on April 06, 2022.
Prognosis
Where this bill stands today.
Odds of enactment
HighHow often bills like it became law.
-
Enacted
Current position in the legislative process.
-
1 sponsor
1 primary, 0 co-sponsors signed on.
-
Cleared a recorded vote
Passed 7 recorded votes so far.
Prognosis reads this bill's own signals — stage, sponsorship breadth, committee status, recorded votes and cross-state momentum. Odds come from a model trained on which bills have become law.
Summary
Drug Control Act; Schedule I; Schedule II; Schedule IV; Schedule V. Adds certain chemicals to the Drug Control Act. The Board of Pharmacy has added these substances in an expedited regulatory process. A substance added via this process is removed from the schedule after 18 months unless a general law is enacted adding the substance to the schedule. This bill is identical to HB 193.
Bill Text
What changed in the latest version
774 added · 736 removedPlain-language change summary
The latest version of SB 759 includes specific updates to the list of controlled substances under Schedule I of the Drug Control Act in Virginia. Notably, several new substances have been added, such as Brorphine and Metonitazene, while some existing descriptions were revised for clarity. These changes are important as they reflect updated evidence about harmful drugs, enhancing public safety by ensuring that more dangerous substances are properly regulated.
SESSION ENROLLED VIRGINIA ACTS OF ASSEMBLY ––-- 2022 SESSION CHAPTER E115 An Act to amend and reenact §§ 54.1-3446, 54.1-3448, 54.1-3452, and 54.1-3454 of the Code of N Virginia, relating to Drug Control Act;
R O [S 759] Approved LApril L6, 2022 Be it enacted by the General Assembly of Virginia:
That §§ 54.1-3446, 54.1-3448, 54.1-3452, and 54.1-3454 of the Code of Virginia are amended aEdand reenacted as follows:
D§ The54.1-3446. controlled substances listed in this section are included in Schedule I:
Schedule I.
The controlled substances listed in this section are included in Schedule I:
Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers, esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers andand1-{1-[1-(4-bromophenyl)ethyl]-4-piperidinyl}-1,3-dihydro-2H-benzimidazol-2-one salts(other isname: possible within the specific chemical designation:
1-{1-[1-(4-bromophenyl)ethyl]-4-piperidinyl}-1,3-dihydro-2H-benzimidazol-2-one (other name:
2-methyl AP-23B);AP-237);
51-methyl-4-phenyl-4-propionoxypiperidine 2-[(4-methoxyphenyl)methyl]-N,N-diethyl-5-nitro-1H-benzimidazole-1-ethanamine (other name:
EMPPP); Metonitazene);
R2-[(4-methoxyphenyl)methyl]-N,N-diethyl-5-nitro-1H-benzimidazole-1-ethanamine 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-aceta(other(other name:
Metonitazene);
2-methoxy-N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-acetamide (other name:
Allylprodine;
Betaprodine;
Dipipanone;butyrate;Dioxaphetylbutyrate;
Dipipanone;
Morpheridine;orphan;Levophenacylmorphan;
Morpheridine;
of 13 N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide (other name:
Tetrahydrofuranyl of 13 fentanyl);
N,N-diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-(otherN,N-diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine (other name:
of 13 2-(3,4-dichlorophenyl)-N-[2-(dimethylamino)cyclohexyl]-N-methyl acetamide (other name:
OcfeEtanil);Ocfentanil);
N N-phenyl-2-methyl-N-[1-(2-phenylethyl)-4-piperidinyl]-propanamide (other name:
Isobutyryl feRtanyl);fentanyl);
N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-cyclopentanecarbox(otherof 13 N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-cyclopentanecarboxamide (other name:
Cyclopentyl fenN-phenyl-N-(1-methyl-4-piperidinyl)-propanamidefentanyl); (other name:
N-phenyl-N-(1-methyl-4-piperidinyl)-propanamide (other name:
O N-[2-(dimethylamino)cyclohexyl]-N-methyl-1,3-benzodioxole-5-carboxamide (other names:
L 3,4-methylenedioxy U-47700 or 3,4-MDO-U-47700);
L N-phenyl-N-[4-phenyl-1-(2-phenylethyl)-4-piperidinyl]-propanamide (other name:
4-phenylfentaEyl);4-phenylfentanyl);
D N-[2-(dimethylamino)cyclohexyl]-N-phenylfuran-2-carboxamide (other name:
U-47700).chloro-N-[2-(dimethylamino)cyclohexyl]-N-isopropyl-benzamide3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-isopropyl-benzamide (other name:
Isopropyl 2.U-47700).
2.
S Acetorphine;
7 Acetyldihydrocodeine;
Show all 182 changed lines (142 more)
9 Benzylmorphine;
R Codeine methylbromide;
Desomorphine;
Myrophine;-Oxide;Morphine-N-Oxide;
Myrophine;
Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation, which contains any quantity of the following hallucinogenic substances, or which contains any of its salts, isomers, and salts of isomers, whenever the existence of such salts, isomers, only,and thesalts termof "isomer"isomers includesis possible within the optical,specific position,chemical anddesignation geometric(for isomers):purposespurposes of this subdivision Alpha-ethyltryptamineonly, (somethe tradeterm or"isomer" otherincludes names:the optical, position, and geometric isomers):
Alpha-ethyltryptamine (some trade or other names:
Diethyltryptamine;
of 13 2,5-dimethoxy-4-ethylamphetamine (DOET);
of 13 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo [b,d] pyran;
of 13 4-Ethylmethcathinone (other name:
E Beta-keto-methylbenzodioxolylpentanamine (other names:
N Alpha-methylamino-valerophenone (other name:
R 3,4-Dimethylmethcathinone (other name:
4-methyl-alpha-pyrrolidinopropiophenone (other name:
MPPP);
25-I, O 25I-NBOMe, 2C-I-NBOMe);
L Methoxetamine (other names:
Lof 13 4-Fluoroamphetamine (other name:
E 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (other name:
D 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (other name:
2-(2,5-Dimethoxyphenyl)ethanamine (other name:
2C-H);
S 4-chloro-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (other names:
7 2C-C-NBOMe, 25C-NBOMe, 25C);
9 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (other names:
R 2C-B-NBOMe, 25B-NBOMe, 25B);
Alpha-pyrrolidinobutiophenone (other name:
alpha-PBP);
1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-1-pentanone (other name:
N-ethylpentylone);
3-methoxy PCP);pentylone);PCP);
1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)-1-pentan(other1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)-1-pentanone (other names:
3,4-tetramethylene-alpha-pyrrolidinovalerophenone (other name:
TH-PVP);
Allylescaline);VP);Allylescaline);
6-ethyl-6-nor-lysergic acid diethylamide (other name:
ETH-LAD);
AL-LAD);;AL-LAD);
of 13 2-(methylamino)-2-phenyl-cyclohexanone (other name:
of 13 5-methoxy-N,N-dibutyltryptamine (other name:
of 13 Aminorex (some trade or other names;
E Cathinone (some trade or other names:
R Ethylamphetamine;
Fenethylline;piperidin-2-yl)acetateEthyl phenyl(piperidin-2-yl)acetate (other name:
OFenethylline; Methcathinone (some other names:
Methcathinone (some other names:
L alpha-(methylamino)-propiophenone;
L methylcathinone;
E N-Benzylpiperazine (some other names:
N, N-alpha-trimethyl-benzeneethanamine, N, D N-alpha-trimethylphenethylamine) N,N-alpha-trimethyl-benzeneethanamine, N,N-alpha-trimethylphenethylamine);
Isopropyl-2-phenyl-2-(2-piperidinyl)acetateMethyl 2-(4-fluorophenyl)-2-(2-piperidinyl)acetate (other name:
Isopropylphenidate);lphenidate);4-fluoromethylphenidate);
of 13 Isopropyl-2-phenyl-2-(2-piperidinyl)acetate (other name:
Isopropylphenidate);
Any substance that contains one or more cannabimimetic agents or that contains their saltS,salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isome7sisomers is possible within the specific chemical designation, and any preparation, mixture, or substance c9ntaining,containing, or mixed or infused with, any detectable amount of one or more cannabimimetic agents.
R a.
2-(3-hydroxycyclohexyl)phenol with substitution at the 5-position of the phenolic ring by alkyl or alk3-(1-naphthoyl)indolealkenyl, or 1H-indol-3-yl-(1-naphthyl)methane with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indolecyclohexyl ring to any extent, whether or not substituted on the naphthoyl or naphthyl ring to any extent;
3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the naphthoyl or naphthyl ring to any extent;
3-phenylacetylindole or 3-benzoylindole with substitution at the nitrogen atom of the indole ring, whether or not further substituted in the indole ring to any extent, whether or not substituted on the phenyl ring to any extent;
N-(adamantyl)-indole-3-carboxamide with substitution at the nitrogen atom of the indole ring, whether or not further substituted on the indole ring to any extent, whether or not substituted on the adamantyl ring to any extent;
anddand on the indole ring to any extent, whether or not substituted on the N-(adamantyl)-indazole-3-carboxamide with substitution at a nitrogen atom of the indazole ring, whether or not further substituted on the indazole ring to any extent, whether or not substituted on the adamantyl ring to any extent.
1-butyl-3-(1-naphthoyl)indole (other name:
JWH-073);
of 13 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (other name:
Pravadoline (4-methoxyphenyl)-[2-methyl-1-(2-(4-morpholinyl)ethyl)indoll]methanone(4-methoxyphenyl)-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-y l]methanone (other name:
of 13 N-adamantyl-1-fluoropentylindole-3-carboxamide (other name:
N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxa(otherN-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide (other name:
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxam ide N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carbo(otherN-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamid(other names:
N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-[(4-fluorophenyl)methyl]-1H-indaz3-carboxamideN-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-[(4-fluorophenyl)methyl]-1H-indazole- N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carb(othere3-carboxamide N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamid(other name:
Methyl 2-[1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamido]-3methylbutanoate2-[1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamido]-3,3-dmethylbutanoate (other name:
Methyl 2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbuean(other2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoae (other names:
of 13 Naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate (other name:
E AB-CHMICA);
N Quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (other name:
R Methyl N-[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]valinate (other name:
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)indazole-3-carboxamid e N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)indazole-3-carboxamide (other name:
O 5-fluoro-ADB-PINACA);
L 1-(4-cyanobutyl)-N-(1-methyl-1-phenylethyl)-1H-indazole-3-carboxamide (other name:
L Methyl 2-[1-(5-fluoropentyl)-1H-indole-3-carboxamido]-3,3-dimethylbutanoate (other name:
E 5-Fluoro-MDMB-PICA) names:
Ethyl 2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoat e Ethyl D 2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoate (other name:
4-fluoro-MDMB-BUTINACA);utyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoateMethyl 2-[1-4-fluorobutyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (other name:
4-fluoro-MDMB-BUTINACA);
S MDMB-4en-PINACA);
7 Methyl 2-({1-[(4-fluorophenyl)methyl]-1H-indole-3-carbonyl}amino)-3-methylbutanoate (other n9mes:names:
of 13 MMB-FUBICA, AMB-FUBICA);
R Methyl 2-[1-(4-penten-1-yl)-1H-indole-3-carboxamido]-3-methylbutanoate (other names:
5-fluoro-MPP-PICA);luoropentyl)-1H-indole-3-carboxamido]-3-phenylpropanoateMethyl 2-[1-(5-fluoropentyl)-1H-indole-3-carboxamido]-3-phenylpropanoate (other name:
5-fluoro-MPP-PICA);
5-fluoro-EMB-PINACA,Ethyl-2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3-methylbutanoate 5F-AEB);)-1H-indazole-3-carboxamido]-3-methylbutanoate (other names:
5-fluoro-EMB-PINACA, 5F-AEB);
Methyl 2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbuta(other2-(1-(cyclohexylmethyl)-1H-indole-3-carboxamido)-3,3-dimethylbutanoate (other names:
ADB-4en-PINACA).3-dimethyl-1-oxobutan-2-yl)-1-(pent-4-enyl)indazole-3-carboxamideN-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(pent-4-enyl)indazole-3-carboxamide (other name:
ADB-4en-PINACA).
Opium extracts;
of 13 Granulated opium;
of 13 2.
of 13 Phenmetrazine and its salts;
Any substance which contains any quantity of methamphetamine, including its salts, isomers, Endand salts of isomers;
N Lisdexamfetamine, its salts, isomers, and salts of its isomers.
R 4.
Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation which contains any quantity of the following substances having a depressant effect on the central nervous system, including its salts, isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is possible within the specific chemical designation:
L Amobarbital;
L Secobarbital;
E Pentobarbital;
D 5.
Dronabinol ((-)-delta-9-trans tetrahydrocannabinol) in an oral solution in a drug product approved for marketing by the U.S.
Food and Drug Administration.ol)Administration. in an oral solution in a drug product approved for 6.
6.
S Phenylacetone.
7 b.
9 1-phenylcyclohexylamine;
R 1-piperidinocyclohexanecarbonitrile (other name:
The§ controlled54.1-3452. substances listed in this section are included in Schedule IV unless specifically excepted or listed in another schedule:
Schedule IV.
The controlled substances listed in this section are included in Schedule IV unless specifically of 13 excepted or listed in another schedule:
Bromazepam;;Brexanolone;
Bromazepam;
Cloxazolam;;Clotiazepam;
Cloxazolam;
Flurazepam;
of 13 Haloxazolam;
of 13 Fenfluramine;
Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, of 13 or preparation which contains any quantity of the following substances, including their salts:
E Eluxadoline (including its optical isomers and its salts, isomers, and salts of isomers);
NPentazocine. 6.
The6. Board may except by regulation any compound, mixture, or preparation containing any depressant substance listed in subdivision 1 from the application of all or any part of this chapter if the compound, mixture, or preparation contains one or more active medicinal ingredients not having O depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances which have a depressant effect on the central nervous system.
LThe §Board 54.1-3454.may except by regulation any compound, mixture, or preparation containing any depressant substance listed in subdivision 1 from the application of all or any part of this chapter if the compound, mixture, or preparation contains one or more active medicinal ingredients not having a depressant effect on the central nervous system, and if the admixtures are included therein in combinations, quantity, proportion, or concentration that vitiate the potential for abuse of the substances which have a depressant effect on the central nervous system.
§ 54.1-3454.
The controlled substances listed in this section are included in Schedule V:
Not more than 100 milligrams of ethylmorphine, or any of its salts, per 100 milliliters or per 100 grams;
more than 100 milligrams of ethylmorphine, or any of its salts, per 100 milliliters or pSr 100 Not more than 2.5 milligrams of diphenoxylate and not less than 25 micrograms of atropine sulfate per dosage unit;
5 Not more than 100 milligrams of opium per 100 milliliters or per 100 grams;
E Not more than 0.5 milligrams of difenoxin and not less than 25 micrograms of atropine sulfate per dosage unit.
The Board may except by regulation any compound, mixture, or preparation containing any suchdepressant substancessubstance solisted exceptedin maysubdivision be1 dispensedfrom pursuantthe toapplication §of 54.1-3416.allall or any part of this chapter and 2.such substances so excepted may be dispensed pursuant to § 54.1-3416.
2.
Unless specifically excepted or unless listed in another schedule, any material, compound, mixture, or preparation that contains any quantity of the following substances having a depressant effect on the cenBrivaracetamof ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl]13 butanamide)central (alsonervous referredsystem, toincluding asits BRV;salts:
Brivaracetam ((2S)-2-[(4R)-2-oxo-4-propylpyrrolidin-1-yl] butanamide) (also referred to as BRV;
commitment.2.
PursuantThat to § 30-19.1:4 of the Codeprovisions of Virginia,this theact estimatedmay amountresult ofin thenta ornet necessaryincrease appropriationin is $0 for periods of imprisonment inor statecommitment. adult correctional facilities and $0 for periods of commitment to the custody of the Department of Juvenile Justice.
Pursuant to § 30-19.1:4 of the Code of Virginia, the estimated amount of the necessary appropriation is $0 for periods of imprisonment in state adult correctional facilities and $0 for periods of commitment to the custody of the Department of Juvenile Justice.
Show all 182 changed rows (142 more)
Action History
-
Approved by Governor-Chapter 115 (effective 7/1/22)
-
Governor's Action Deadline 11:59 p.m., April 11, 2022
-
Enrolled Bill Communicated to Governor on March 11, 2022
-
Signed by President
-
Signed by Speaker
-
Impact statement from DPB (SB759ER)
-
Enrolled
-
VOTE: Passage (91-Y 7-N)
-
Passed House (91-Y 7-N)
-
Read third time
-
Read second time
-
Reported from Health, Welfare and Institutions (18-Y 2-N)
-
Referred to Committee on Health, Welfare and Institutions
-
Read first time
-
Placed on Calendar
-
Passed Senate (40-Y 0-N)
-
Reconsideration of passage agreed to by Senate (40-Y 0-N)
-
Read third time and passed Senate (39-Y 0-N)
-
Read second time and engrossed
-
Constitutional reading dispensed (39-Y 0-N)
-
Reported from Education and Health (15-Y 0-N)
-
Impact statement from DPB (SB759)
-
Impact statement from VCSC (SB759)
-
Referred to Committee on Education and Health
-
Presented and ordered printed 22104959D
Sponsors
- Stephen D. Newman · Primary
Sponsorship breakdown
Export CSV (upgrade) →1 sponsors · 0 co-sponsors · 147 not signed on · 7 voted No
Sponsors (1)
Co-sponsors (0)
None.
Not signed on (147)
147 members have not signed on to this bill.
Show all 147 →"Not signed on" means a member has not sponsored or co-sponsored this bill — it does not imply opposition. Members flagged Voted No have a recorded No vote on this bill.
Votes
| Party | Yea | Nay | Present | Not Voting |
|---|---|---|---|---|
| Unaffiliated | 90 | 7 | 0 | 2 |
| Total | 90 | 7 | 0 | 2 |
| % of votes cast | 91% | 7% | 0% | 2% |
How each member voted (99)
| Party | Yea | Nay | Present | Not Voting |
|---|---|---|---|---|
| Unaffiliated | 18 | 2 | 0 | 2 |
| Total | 18 | 2 | 0 | 2 |
| % of votes cast | 82% | 9% | 0% | 9% |
How each member voted (22)
| Member | Party | Vote |
|---|---|---|
| March, Marie E. | — | Yea |
| Adams, Dawn M. | — | Not Voting |
| Bell, Robert B. | — | Yea |
| C.E. Cliff Hayes, Jr. | — | Yea |
| Christopher T. Head | — | Yea |
| Edmunds, James E., II | — | Yea |
| Fariss, C. Matthew | — | Not Voting |
| Guzman, Elizabeth R. | — | Yea |
| H. Otto Wachsmann, Jr. | — | Yea |
| Hudson, Sally L. | — | Nay |
| Karrie K. Delaney | — | Yea |
| Kathy K.L. Tran | — | Yea |
| M. Keith Hodges | — | Yea |
| Marcia S. "Cia" Price | — | Nay |
| Mike A. Cherry | — | Yea |
| Orrock, Robert D., Sr. | — | Yea |
| Patrick A. Hope | — | Yea |
| Phillip A. Scott | — | Yea |
| Robinson, Roxann L. | — | Yea |
| Rodney T. Willett | — | Yea |
| Sickles, Mark D. | — | Yea |
| Wendell S. Walker | — | Yea |
| Party | Yea | Nay | Present | Not Voting |
|---|---|---|---|---|
| Unaffiliated | 40 | 0 | 0 | 0 |
| Total | 40 | 0 | 0 | 0 |
| % of votes cast | 100% | 0% | 0% | 0% |
How each member voted (40)
| Party | Yea | Nay | Present | Not Voting |
|---|---|---|---|---|
| Unaffiliated | 40 | 0 | 0 | 0 |
| Total | 40 | 0 | 0 | 0 |
| % of votes cast | 100% | 0% | 0% | 0% |
How each member voted (40)
| Party | Yea | Nay | Present | Not Voting |
|---|---|---|---|---|
| Unaffiliated | 39 | 0 | 0 | 1 |
| Total | 39 | 0 | 0 | 1 |
| % of votes cast | 98% | 0% | 0% | 3% |
How each member voted (40)
| Party | Yea | Nay | Present | Not Voting |
|---|---|---|---|---|
| Unaffiliated | 39 | 0 | 0 | 1 |
| Total | 39 | 0 | 0 | 1 |
| % of votes cast | 98% | 0% | 0% | 3% |
How each member voted (40)
| Party | Yea | Nay | Present | Not Voting |
|---|---|---|---|---|
| Unaffiliated | 15 | 0 | 0 | 0 |
| Total | 15 | 0 | 0 | 0 |
| % of votes cast | 100% | 0% | 0% | 0% |
How each member voted (15)
| Member | Party | Vote |
|---|---|---|
| Barker, George L. | — | Yea |
| Cosgrove, John A., Jr. | — | Yea |
| David R. Suetterlein | — | Yea |
| Dunnavant, Siobhan S. | — | Yea |
| Edwards, John S. | — | Yea |
| Hashmi, Ghazala F. | — | Yea |
| Howell, Janet D. | — | Yea |
| L. Louise Lucas | — | Yea |
| Lewis, Lynwood W., Jr. | — | Yea |
| Mamie E. Locke | — | Yea |
| Mark J. Peake | — | Yea |
| Newman, Stephen D. | — | Yea |
| Petersen, J. Chapman | — | Yea |
| Saslaw, Richard L. | — | Yea |
| Todd E. Pillion | — | Yea |
Subjects
Frequently asked questions
- What does SB 759 do?
- Drug Control Act; Schedule I; Schedule II; Schedule IV; Schedule V. Adds certain chemicals to the Drug Control Act. The Board of Pharmacy has added these substances in an expedited regulatory process. A substance added via this process is removed from the schedule after 18 months unless a general law is enacted adding the substance to the schedule. This bill is identical to HB 193.
- Who sponsors SB 759?
- SB 759 is sponsored by Newman, Stephen D..
- What is the current status of SB 759?
- This bill has been enacted into law. Introduced January 21, 2022. Enacted.
- Where can I track SB 759?
- Track SB 759 free on One Click Politics — get push/email alerts when it moves.
Make your voice heard on SB 759
Find the representatives who decide this bill and tell them where you stand — for yourself, or mobilize your whole list in one click with One Click Politics advocacy software.
Stay ahead of SB 759
Last checked for changes 3 months ago · updated continuously
One Click Politics tracks every bill in Congress and all 50 states.
Track this bill →